Please complete the CAPTCHA to continue
@zoiccapital.com
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
Ian Eliason is listed as Venture Capitalist & Advisor at Zoic Capital, based in United States, United States, United States. AeroLeads shows a work email signal at zoiccapital.com and a matched LinkedIn profile for Ian Eliason.
Ian Eliason previously worked as Partner & Co-founder at Zoic Capital and Investor & Advisor at Hdt Bio. Ian Eliason holds Bachelor Of Science - Bs, Public Health, Finance, Communications from University Of Minnesota.
This section adds company-level context without repeating Ian Eliason's masked contact details.
AeroLeads found 1 current-domain work email signal for Ian Eliason. Compare company email patterns before reaching out.
I've always been curious, trying to cultivate a deeper understanding of the world. That same curiosity has also lead me "off the beaten path" to find keys that unlock simple solutions to big problems.That same mentality led me to co-found Zoic Capital, where my work consists of analysis, diligence, and optimization.Zoic Capital operates as a middleman, pulling in investor capital and deploying it into companies that solve big problems dominantly. In turn, this process allows my team and I to help our portfolio companies and investors:► Develop large scale inclusive IP development strategies► Help connect and codevelop deals with potential strategic acquirersWe are currently the only US-based venture firm focused solely on investing in the seed stage of Medtech, going through a rigorous vetting process with each investment opportunity to ensure that:1. their technological developments represent at least a 10X improvement in the current standard of care2. their technology relies on scientific mechanisms which are fully supported by published literature, independent trials, and personal observation3. in most cases, they have unique hardware and IP coupled with unique software4. the leadership team has the necessary combination of vision and experience to create a transformational company5. they have initial regulatory approval on a short timeline, typically two to four years.Throughout this process, my job is to find the core USP, issues, and areas of improvement for each of our portfolio companies and for each of the opportunities that come across our table. Then, ultimately determine how we can implement tactical insights, providing value to the company, and, as a result, our investors.If you want to learn more about Zoic, the types of companies we invest in, or if you’d like to exchange good reads and travel ideas, send me an email: ian@zoiccapital.comIf you know of an interesting deal for Zoic to look at, feel free to get in touch with my team here: deals@zoiccapital.com
Listed skills include Venture Capital, Start Ups, Leadership, Business Development, and 12 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Seattle, Washington, US
Zoic is an IP centric life sciences venture fund. We are actively seeking to invest in early stage companies that:1. Have technology with a primary medical application; any technology except for those considered a pharmaceutical by the FDA.2. The technology represents 10x magnitudes of improvement over current standard of care, or has no equivalent.3. We.
Seattle, Washington, US
Investor in HDT Bio. A biopharmaceutical company addressing the urgent need for cost-effective vaccines to prevent infectious diseases across the globe.HDT Bio, was formed by a group of experienced entrepreneurs with decades of success in biopharmaceutical research and vaccine development around the world.
Morrisville, North Carolina, US
Investor in Trio Labs. Trio Labs' mission is to improve lives by enabling the next generation of medical devices. Trio fabricates precision metal parts with unmatched fine resolution that scale seamlessly from prototyping though high volume manufacturing. The Resin Infused Powder Lithography (RIPL) process reduces costs and manufacturing times for existing.
Ambler, PA, US
Investor in Chromatan. The future of single-use, column-free purification.Purification of proteins and vaccines is vital to biotechnology. Innovation in this industry has lagged, leading to manufacturing bottlenecks, especially in antibody production. ChromaTan has developed Continuous Countercurrent Tangential Chromatography (CCTC) - a new column-free and.
Fremont, California, US
Investor in Probius. Bridging biology and AI, to improve human health. Empowering the future of life science research.
Montreal, CA
ODS Medical Inc. is a medical device company that seeks to commercialize our exclusive Raman spectroscopy system for real-time detection of tissue abnormalities through the development, manufacture and sales of products for a range of clinical settings.
Montréal, QC, CA
Investor in Optina Diagnostics. Optina aims to transform memory loss detection and understanding through a simple eye exam offered in near-patient clinicsOptina at the forefront of innovation To deliver new insights on the most complex and least understood organ, the brain.Alzheimer’s disease is a leading cause of disability and dependency in later life..
Boston, MA, US
Investor in BioRosa. The Future of Autism Spectrum Disorder DetectionBioROSA’s Test Provides a New Way to Detect ASDBioROSA is developing a highly accurate blood test that will detect ASD in children as young as 18 months.Early Intervention FollowsA positive BioROSA test can allow for early intervention services to begin. Early intervention has been shown.
San Carlos, California, US
Investor in InnoVein. InnoVein, a Y Combinator and venture backed medical device company, is developing a first-of-its-kind valve replacement to offer patients their first definitive cure. Its novel award-winning technology is predicated on decades of cardiac and arterial approaches.In aggregate, the InnoVein founding team has invented and brought over 15.
San Diego, CA, US
Investor in Juno Diagnostics. Juno Diagnostics has developed the next generation of non-invasive prenatal tests so that all women can access a higher standard of care.The company founders worked together to pioneer the development and commercialization of the first cell-free DNA-based non-invasive prenatal screen (NIPS) in the United States, trusted by.
Quick answers generated from the profile data available on this page.
Ian Eliason works for Zoic Capital.
Ian Eliason is listed as Venture Capitalist & Advisor at Zoic Capital.
AeroLeads has found 1 work email signal at @zoiccapital.com for Ian Eliason at Zoic Capital.
Ian Eliason is based in United States, United States, United States while working with Zoic Capital.
Ian Eliason has worked for Zoic Capital, Hdt Bio, Trio Labs, Inc., Chromatan, Inc, and Probius.
You can use AeroLeads to view verified contact signals for Ian Eliason at Zoic Capital, including work email, phone, and LinkedIn data when available.
Ian Eliason holds Bachelor Of Science - Bs, Public Health, Finance, Communications from University Of Minnesota.
Ian Eliason is listed with skills including Venture Capital, Start Ups, Leadership, Business Development, Strategy, Valuation, Due Diligence, and Biotechnology.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts